Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation

Novosad, J A; Kalantaridou, Sophia Ν.; Tong, Zhi-Bin; Nelson, Lawrence M.

doi:10.1186/1472-6874-3-2

Cited by 81 publications

(57 citation statements)

References 28 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, there was no specificity and it varied according to source of ovarian tissue and maturation state. Novosad et al (2003) reported poor specificity with a commercially available kit which tested positive in nearly one-third of normally menstruating women [12]. The group thus affirmed that IIF is not a reliable tool to detect AOA.…”

Section: Discussionmentioning

confidence: 96%

“…Hence, it is essential to assess the presence of serum AOA when a woman first presents herself with infertility to the clinician. Specificity of AOA testing has been questioned and the available tests reported in literature have been challenged [12] due to high rates of false positives seen using sera from normal fertile controls. This problem of non-specificity has been overcome in a specific, simple and non-invasive diagnostic test developed by us [13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Can anti-ovarian antibody testing be useful in an IVF-ET clinic?

Pires

Parikh

Mande

et al. 2010

J Assist Reprod Genet

View full text Add to dashboard Cite

Objective To establish importance of anti-ovarian antibodies (AOA) testing in infertile women. Design A clinical reproductive outcome comparative study between two groups of women undergoing IVF-ET. Group 1 consists of women tested positive for AOA, put on corticosteroid therapy, reverted to AOA negative and then taken up for IVF-ET. Group 2 were seronegative for AOA. Setting Major urban infertility reference centre and National research institute. Results AOA positive serum samples were sent periodically to re-investigate presence of AOA after corticosteroid therapy and women turned AOA negative were taken up for IVF-ET. Of the 70/138 women in group 1 who were treated with corticosteroids and turned seronegative for AOA, 22/70 were poor responders and needed donor oocyte-recipient cycles. Results demonstrated that fertilization and clinical pregnancy rates between both groups are comparable. Nevertheless, it is also observed that there is poor response to stimulation protocol, smaller number of oocytes retrieved and more spontaneous abortions in group 1 women. Hence not all outcomes following the treatment are comparable between the two groups. Usefulness of the test was established in two case studies. Conclusions AOA testing could be included in the battery of tests investigating and treating infertility.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Can anti-ovarian antibody testing be useful in an IVF-ET clinic?

Pires

Parikh

Mande

et al. 2010

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…Ovarian antibodies lack specificity, and testing for them is not warranted. 21 Pelvic ultrasonography identifies cases involving enlarged, multifollicular ovaries, which may undergo torsion, such as in isolated 17,20-lyase deficiency or autoimmune oophoritis (Table 2). An ovarian biopsy does not provide information that is helpful in the management of primary ovarian insufficiency and is therefore not indicated; pregnancy may occur even after examination of a biopsy specimen has shown that follicles are absent.…”

Section: Discussionmentioning

confidence: 99%

Primary Ovarian Insufficiency

Cooper¹,

Covington²,

Nelson³

2010

Amenorrhea

View full text Add to dashboard Cite

A 30-year-old woman presents with a history of no menses since she stopped taking oral contraceptives 6 months ago in order to conceive. She had undergone puberty that was normal in both timing and development, with menarche at 12 years of age. At 18 years of age, she started taking oral contraceptives for irregular menses. She reports stress at work. Her weight is 59 kg, and her height 1.66 m; her body-mass index (the weight in kilograms divided by the square of the height in meters) is 21.3. There is no galactorrhea, hirsutism, or acne. The pelvic examination is normal, a pregnancy test is negative, the prolactin level is normal, and the follicle-stimulating hormone (FSH) level is in the menopausal range. How should she be evaluated and treated? THE CLINICAL PROBLEMThe ovary is unique in the endocrine system in that an entirely new secretory structure is developed within it each month -the graafian follicle, which arises from a microscopic primordial follicle. Menopause, defined as the permanent cessation of menses, results from the depletion of potentially functional primordial follicles. The mean (±SD) age at the time of natural menopause is 50±4 years. 1 Menopause before the age of 40 years is considered to be premature.Primary ovarian insufficiency is the preferred term for the condition that was previously referred to as premature menopause or premature ovarian failure; other terms used for this condition include primary ovarian failure and hypergonadotropic hypogonadism, as well as the misnomer, gonadal dysgenesis. 2,3 The condition is considered to be present when a woman who is less than 40 years old has had amenorrhea for 4 months or more, with two serum FSH levels (obtained at least 1 month apart) in the menopausal range. 4,5 The condition differs from menopause in that there is varying and unpredictable ovarian function in approximately 50% of cases, and about 5 to 10% of women conceive and deliver a child after they have received the diagnosis. 4,6-9 Thus, the term "primary ovarian insufficiency," as originally suggested by Albright, meets the need to describe a continuum of impaired ovarian function rather than a dichotomous state. 2,3 This term may also be less stigmatizing than the terms that were used previously.Address reprint requests to Dr. Nelson at the Integrative Reproductive Medicine Unit, NICHD-Intramural Research Program on Reproductive and Adult Endocrinology, CRC, Rm. 1-3330, 10 Center Dr., MSC-1103, Bethesda, MD 20892, or at lawrence_nelson@nih.gov. Dr. Nelson reports being an inventor on three United States patents directed to MATER (a potential antigen in autoimmune primary ovarian insufficiency) and its applications (U.S. patent numbers 7,189,812; 7,217,811; and 7,432,067), as well as one pending United States patent application (U.S. patent application number 11/586,160) and foreign counterparts. No other potential conflict of interest relevant to this article was reported. Primary ovarian insufficiency occurs through two major mechanisms: follicle dysfunction and foll...

show abstract

“…O valor preditivo do teste disponível no mercado é pobre como um método para identificar as mulheres com FOP. Num estudo de 26 mulheres com FOP e 26 mulheres com ciclos normais, 50% das mulheres com FOP e 31% de mulheres normais tinham anticorpos antiovarianos (27).…”

Section: Autoanticorpos Circulantesunclassified

Falência ovariana precoce

Assumpção

2014

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOEste artigo irá rever os diversos aspectos da falência ovariana prematura (FOP), definida como o desenvolvimento de hipogonadismo em mulheres antes dos 40 anos, desde a etiopatogenia, com discussões sobre as causas autoimunes, iatrogênicas, ou anormalidades do cromossomo X assim como manifestações clínicas, diagnóstico e tratamento. A maioria das mulheres com essa condição não possui uma história menstrual, específica do desenvolvimento da FOP, mas a infertilidade associada ao diagnóstico é o aspecto mais problemático da doença. INTRODUÇÃO M uitas revisões recentes têm discutido o nome apropriado para essa condição, embora muitos pacientes e médicos prefiram o termo menopausa prematura, um termo simples e compreensível que pode ser explicado aos amigos e familiares, mas implica certa sensação de permanência, no entanto, a ovulação e a gravidez podem ocorrer em um momento posterior, por vezes anos após o diagnóstico (1-3).A falência ovariana precoce (FOP) é definida como falência gonadal antes dos 40 anos de idade. A incidência é de aproximadamente 1 em 250 mulheres com idade de 35 anos e de 1 em 100 com idade de 40 anos. É idiopática em 74% a 90% das pacientes. Algumas pacientes com FOP podem produzir estrogênio, ovular, e, em 5% a 10% dos casos, conceber e ter uma gravidez e parto sem alterações, assim como ter a função ovariana intermitente (sem amenorreia associada) e menstruação espontânea (embora anormalidades da função menstrual estejam presentes) (3-9).Neste artigo, o termo a ser utilizado será falência ovariana precoce (FOP), o qual é adequado e descreve seu diagnóstico. ETIOLOGIA E PATOGENIAEntender a causa da FOP exige uma compreensão do processo de foliculogênese em que muitas das molé-culas que regulam a série de eventos na maturação folicular estão envolvidas. O processo de maturação folicular ocorre de forma contínua e pode demorar até um ano para proceder o início do crescimento de um folículo primordial até se tornar um folículo ovulatório. A granulosa e as células somáticas da teca sintetizam e secretam fatores de crescimento e diferenciação, fatores de transcrição, como o FOXL2, inibina e hormônios esteroides que são regulados pelas http://dx

show abstract

Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation

Abstract: Background: Ovarian antibodies as detected by indirect immunofluorescence have been used to detect ovarian autoimmunity, but to our knowledge the rate of false positive findings using this method has never been reported.

Cited by 81 publications

References 28 publications

Can anti-ovarian antibody testing be useful in an IVF-ET clinic?

Can anti-ovarian antibody testing be useful in an IVF-ET clinic?

Primary Ovarian Insufficiency

Falência ovariana precoce

Contact Info

Product

Resources

About